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Article focus
  Hip prosthetic joint infection (PJI) is an 
uncommon, but serious, complication of 
hip arthroplasty.
  epidemiological evidence from the 
united Kingdom on revision for PJI is out 
of date and the majority of available stud-
ies are single-centre retrospective cohorts.
  We identified no contemporary studies 
reporting the frequency or changes in 
use over time of single- and two-stage 
revision procedures.
Key messages
  The overall risk of revision for PJI was 
0.4% after primary total hip arthroplasty 
(THA) and 1.6% after aseptic revision 
THA.
  Between 2005 and 2013, there was an 
increase in the risk of revision due to PJI in 
the three months following index THA, 
with no increase after three months.
  The annual volume of revision hip proce-
dures for treatment of PJI increased 2.6-
fold between 2005 and 2013, with an 
increase in the use of single-stage revision 
from 18% in 2005 to 39% in 2014.
Strengths and limitations
  The dataset on which this analysis was 
performed is one of the largest joint 
arthroplasty registers.
Revision for prosthetic joint infection 
following hip arthroplasty
evIdeNce fRom THe NATIoNAl JoINT RegIsTRy
Objectives
We used the national Joint Registry for england, Wales, northern Ireland and the Isle of Man 
(nJR) to investigate the risk of revision due to prosthetic joint infection (pJI) for patients 
undergoing primary and revision hip arthroplasty, the changes in risk over time, and the 
overall burden created by pJI.
Methods
We analysed revision total hip arthroplasties (THAs) performed due to a diagnosis of pJI 
and the linked index procedures recorded in the nJR between 2003 and 2014. The cohort 
analysed consisted of 623 253 index primary hip arthroplasties, 63 222 index revision hip 
arthroplasties and 7585 revision THAs performed due to a diagnosis of pJI. The prevalence, 
cumulative incidence functions and the burden of pJI (total procedures) were calculated. 
overall linear trends were investigated with log-linear regression.
Results
We demonstrated a prevalence of revision THA due to prosthetic joint infection of 0.4/100 
procedures following primary and 1.6/100 procedures following revision hip arthroplasty. 
The prevalence of revision due to pJI in the three months following primary hip arthroplasty 
has risen 2.3-fold (95% confidence interval (cI) 1.3 to 4.1) between 2005 and 2013, and 3.0-
fold (95% cI 1.1 to 8.5) following revision hip arthroplasty. over 1000 procedures are per-
formed annually as a consequence of hip pJI, an increase of 2.6-fold between 2005 and 2013.
Conclusions
Although the risk of revision due to pJI following hip arthroplasty is low, it is rising and, 
coupled with the established and further predicted increased incidence of both primary and 
revision hip arthroplasty, this represents a growing and substantial treatment burden.
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  The recording of PJI as an indication for surgery is 
according to the opinion of the treating surgeon at 
the time of surgery. As such, the diagnosis has not 
necessarily been referenced against a benchmark set 
of criteria.
  While the National Joint Registry now represents a 
mature dataset with long-term follow-up, there is still 
a substantial number of patients undergoing revision 
THA where there is no record of a linked primary THA.
introduction
Hip prosthetic joint infection (PJI) is an uncommon, but 
serious, complication of hip arthroplasty,1 with an inci-
dence of 0.6% to 2.2%.2-4 Analysis of national registry 
data from four Nordic countries between 1995 and 2009 
demonstrated an increase in the proportion of primary 
hip arthroplasties revised for PJI.2 evidence available from 
the united Kingdom is out of date and primarily derived 
from single-centre retrospective cohort studies.3,5
surgical site infections can have a devastating effect 
on patients and these infections are sometimes fatal.6 PJI 
may be managed with surgical debridement, antibiotic 
treatment and implant retention with exchange of modu-
lar components (dAIR).7 This is commonly used for treat-
ment of acute PJI with pathogens susceptible to antibiotics 
and in patients unfit for major surgery. However, lifelong 
suppressive antibiotic treatment may be required and 
45% to 52% of patients receiving dAIR may subsequently 
need revision of their implants.8 Rates of revision of 
implants following treatment with dAIR may be lower 
with strict selection criteria,9 but larger single-centre 
cohort studies suggest that the rate of revision of implants 
is around 20% by two years.7 About half of patients who 
are diagnosed with PJI subsequently undergo major revi-
sion surgery.3,10 single-stage or two-stage revision sur-
gery may be undertaken. for many surgeons, the revision 
of hip arthroplasties for PJI by a two-stage approach is 
considered the benchmark11 but there is increasing sup-
port for a single-stage approach.12 Both interventions 
achieve eradication of infection in about 90% of cases in 
the two years following revision12 and are associated with 
significant morbidity and cost.13 We identified no con-
temporary studies reporting the frequency of use or 
changes in use over time of the different revision 
strategies.
We analysed the National Joint Registry for england, 
Wales, Northern Ireland and the Isle of man (NJR), a large 
arthroplasty database established in April 2003,14 to 
obtain representative and contemporary evidence on the 
burden of revision surgery for hip PJI in england and 
Wales.
our specific aims were to:
- describe the prevalence rates of revision surgery 
for the treatment of hip PJI and their time trends 
broken down by time from index surgery to revi-
sion for infection;
- describe the cumulative incidence functions;
- estimate the national burden of hip PJI at health 
service level by accounting for all of the revisions 
and re-revision surgeries performed for hip PJI reg-
istered in the NJR.
The above aims are reported by type of index surgery, 
i.e. primary or revision surgery for aseptic indications.
Materials and Methods
Data source. In this observational study, we report anal-
yses of data from the NJR. The registry was established 
in 2003 and includes details of primary and revision hip 
arthroplasties performed in england and Wales. data 
entry for Northern Ireland commenced in february 2013 
and for the Isle of man in 2015, and this data is therefore 
excluded from these analyses.
We grouped procedures as index surgeries and subse-
quent revision surgeries for the treatment of hip PJI. All 
index surgeries performed between 01 April 2003 and 31 
december 2013 were included (to give a minimum 
12-month follow-up). All revision surgeries performed as 
a consequence of PJI between 01 January 2003 and 31 
december 2014 were considered.
Ethics approval and patient consent. Patient consent was 
obtained for data collection by the NJR. According to 
the specifications of the NHs Health Research Authority, 
separate informed consent and ethical approval were not 
required for the present study.
index surgeries. Index surgeries included all primary pro-
cedures and all revision procedures performed for indica-
tions other than PJI. The index revision procedures have 
been labelled ‘aseptic revision’ procedures to indicate 
that they were not performed due to PJI as indicated on 
the NJR data collection forms. Revisions not performed 
for PJI but that were performed on a hip previously oper-
ated on due to PJI were excluded from the index sur-
gery cases. Any procedure with infection as one of the 
reported indications for surgery on the data collection 
form was considered as a revision for PJI. Revision pro-
cedures were classified as a single-stage, a stage one of 
a two-stage revision, a stage two of a two-stage revision 
procedure, or a hip excision. dAIR procedures with mod-
ular exchange are recorded in the NJR dataset as single-
stage revision procedures. To identify which procedures 
recorded as single-stage revisions were dAIRs with mod-
ular exchange, as opposed to complete single-stage revi-
sions where implants fixed to bone are also revised, the 
component level data were examined for both the index 
and revision procedures where available. Procedures 
recorded as single-stage revisions where only modular 
components were added (‘liner’, ‘femoral head’ and/or 
‘proximal stem component’) were defined as dAIRs with 
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modular exchange. Those where implants fixed to bone 
were implanted (‘cup’, non-modular or non-proximal 
‘stem component’) were defined as single-stage revi-
sions. debridements where the surgeon either elects not 
to exchange modular components when they are pres-
ent or where modular exchange is not possible (e.g. with 
resurfacing or non-modular implants) are not captured 
in the NJR.
Statistical analysis. This was performed with stata se 
14.2 (statacorp lP, college station, Texas).
Prevalence rates of index surgeries performed between 
2003 and 2013, and subsequently revised for an indica-
tion of infection between 2003 and 2014, were derived 
by year and type of index surgery, i.e. primary or ‘aseptic 
revision’ surgeries: number of index surgeries revised for 
PJI/total of index surgeries x 1000. This provides a ‘sur-
geon perspective’ of revision for PJI by describing the 
proportion of hip arthroplasties which required revision 
surgery for the management of infection. The prevalence 
rates were then derived and plotted by time from index 
surgery to revision for infection (within three months, 
between three and six months, six months to one year, 
one to two years, two to three years, three to four years, 
and five to six years). This allowed the investigation of 
time trends in the revision for hip PJI in the short-, mid-, 
and long-term following index primary or aseptic revi-
sion hip arthroplasty. The time elapsed between the 
index and the revision surgery was derived as the differ-
ence in months or years between the recorded procedure 
dates. for two-stage surgeries, the recorded date of the 
stage one of a two-stage revision was selected to indicate 
the date of revision for PJI. log-linear regression, using 
the year of index or revision surgery as a continuous inde-
pendent factor, was used to investigate overall linear 
trends between 2005 and 2013. This period was selected 
as over 85% (proportion of procedure records submitted 
to the NJR compared with the levy returns for the number 
of implants sold) of hip arthroplasties performed in 2005, 
and over 99% of those performed from 2007 onwards, 
had been recorded in the NJR; prior to 2005, the data 
capture of the NJR was < 75%.15 When evidence of a time 
trend was identified (year of surgery, p ⩽ 0.05), the year 
of surgery was re-considered as a categorical variable 
using 2005 as the reference period. estimated relative risk 
and related 95% confidence intervals (cI) quantified the 
relative increase in rates between the period of interest 
and 2005.
To move from a surgical perspective to a patient per-
spective, cumulative incidence functions were derived by 
type of index surgery (primary or aseptic revision).16-18 
They provide the probability of being revised as a conse-
quence of PJI within a specific time period following the 
index surgery, while accounting for the time patients 
were at risk of being revised for a PJI and the competing 
risks of death and revision for an aseptic indication.
The overall ‘burden of PJI’ was analysed using all doc-
umented revision procedures performed between 2003 
and 2014 for an indication of PJI (rather than just those 
with a linked index procedure reported in the NJR), as 
well as any subsequent re-revision procedures in the 
cases, whether they were performed for PJI or another 
indication. This provides a ‘healthcare service perspec-
tive’ of revision for PJI. A total of 3634 patients had hip 
revision procedures performed between 2003 and 2014 
for PJI when there was no index procedure recorded in 
the NJR. The overall burden was reported by the year and 
type of revision surgery. The stage one of a two-stage 
revision and stage two of a two-stage revision were con-
sidered to be one procedure to avoid double counting. 
The same strategy was also used to account for more 
than one first-stage revision of a two-stage revision pro-
cedure (i.e. more than one stage prior to the final stage of 
re-implantation).
Results
There were 623 253 primary and 63 222 aseptic revision hip 
arthroplasties (n = 686 475) recorded in the NJR between 
April 2003 and december 2013 (Table I). A total of 7040 
patients required at least one revision surgery (7585 pro-
cedures) due to hip PJI between 2003 and 2014 (primary 
hip arthroplasty revised for PJI, n = 2705 (2926 proce-
dures), aseptic revision re-revised for PJI, n = 997 (1113 
procedures), revision for PJI but no index surgery recorded 
in the NJR, n = 3338 (3546 procedures)) (fig. 1).
Surgeon perspective. Around 0.43% (95% cI 0.42 to 
0.45) of the primary hip arthroplasties recorded in the 
NJR were subsequently revised due to PJI and 1.58% 
(95% cI 1.48 to 1.67) of the aseptic revision hip arthro-
plasties were similarly revised due to PJI (Table I).
figure 2 shows trends in primary surgeries revised for 
PJI within two years of the index surgery. The revision 
rates of a primary hip arthroplasty for PJI within three 
months of the index procedure increased over time, with 
the rate in 2013 twice that of the rate in 2005: rate ratio 
(RR) 2.29 (95% cI 1.28 to 4.08), time trend (likelihood 
ratio test, p < 0.0001). No evidence of time trends in the 
rates of revision within three to six months, six months to 
one year, and one to two years, was found between 2005 
and 2013. The rates of late revision for PJI decreased over 
time (supplementary fig. a): between two and three 
years (2011 compared with 2005), RR 0.52 (95% cI 0.32 
to 0.84), time trend (likelihood ratio test, p < 0.0001); 
between three and four years (2010 compared with 
2005), RR 0.49 (95% cI 0.31 to 0.80), time trend (likeli-
hood ratio test, p = 0.001); and between four and five 
years (2009 compared with 2005), RR 0.44 (95% cI 0.27 
to 0.73), time trend (likelihood ratio test, p = 0.028).
figure 3 and supplementary figure b show trends in 
aseptic revision surgeries revised for PJI. The proportion 
of aseptic revisions subsequently revised for PJI within 
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three months of the procedure also increased over time, 
RR 3.00 (95% cI 1.06 to 8.51), time trend (likelihood ratio 
test, p = 0.002). No important differences were noted in 
the rates of revision for infection performed at any time 
beyond three months from the index revision surgery (all 
time trend, likelihood ratio test, p-values > 0.1).
patient perspective. figure 4 shows the probability over 
time of revision for infection in patients with an index 
Table i. Primary and aseptic revision arthroplasty procedures revised for a prosthetic hip joint infection (PJI)
primary Aseptic revision
Revised for PJI Prevalence rate Revised for PJI Prevalence rate
 N n Per 1000 procedures, 95% cI N n Per 1000 procedures, 95% cI
2003 14 462 79 5.46 (4.26 to 6.66) 1278 24 18.78 (11.34 to 26.22)
2004 27 992 194 6.93 (5.96 to 7.90) 2439 43 17.63 (12.41 to 22.85)
2005 40 147 269 6.70 (5.90 to 7.50) 3513 61 17.36 (13.04 to 21.68)
2006 47 530 267 5.62 (4.95 to 6.29) 4219 80 18.96 (14.85 to 23.08)
2007 60 470 322 5.32 (4.74 to 5.91) 5725 119 20.79 (17.09 to 24.48)
2008 66 712 375 5.62 (5.05 to 6.19) 6234 136 21.82 (18.19 to 25.44)
2009 67 571 315 4.66 (4.15 to 5.18) 6513 118 18.12 (14.88 to 21.36)
2010 69 902 270 3.86 (3.40 to 4.32) 7124 115 16.14 (13.22 to 19.07)
2011 72 856 226 3.10 (2.70 to 3.51) 8038 114 14.18 (11.60 to 16.77)
2012 76 617 238 3.11 (2.71 to 3.50) 9357 108 11.54 (9.38 to 13.71)
2013 78 994 150 1.90 (1.60 to 2.20) 8782 79 9.00 (7.02 to 10.97)
Total 623 253 2705 4.34 (4.18 to 4.50) 63 222 997 15.77 (14.80 to 16.74)
cI, confidence interval.
Revision arthroplasties performed as a consequence of prosthetic hip joint infection (PJI) recorded in the NJR between 04/2003 and 12/2014 
A. Index primary and index ”aseptic” revision arthroplasties 
    performed between 04/2003-12/2013 and subsequent 
    revision arthroplasties for PJI. 
B. Revision arthroplasties for PJI performed on patients with no 
    previous NJR record. The first revision for PJI was performed 
    between 04/2003-12/2013. These procedures are used to derive 
    the burden of PJI†. 
No record of index surgeryPrimary Aseptic revision
C. Additional index primary, index “aseptic” revision arthroplasties performed between 01/2014 and 12/2014 and unlinked revision arthroplasties 
    for PJI performed between 01/2014 and 12/2014. These procedures are used to derive the burden of PJI† but not used in the other analyses
    as follow-up is < 1 yr.
- At least one revision for PJI n = 296
- Total revisions for PJI‡ n = 301
- Further aseptic re-revisions n = 4
Revised for PJI
- At least one revision for PJI n = 34
- Total revisions for PJI‡ n = 39
- Further aseptic re-revisions n = 1
Revised for PJI
- At least one revision for PJI n = 94
- Total revisions for PJI‡ n = 101
- Further aseptic re-revisions n = 1
Revised for PJI
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Recorded index surgeries* n = 686 475
Primary n = 626 253 Aseptic revision n = 63 222
- At least one revision for PJI n = 2705
- Total revisions for PJI‡ n = 2926
- Further aseptic re-revisions n = 167
- At least one revision for PJI n = 997
- Total revisions for PJI‡ n = 1113
- Further aseptic re-revisions n = 73
Revised for PJI Revised for PJI
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No record of index surgery*
- At least one revision for PJI n = 3338
- Total revisions for PJI‡ n = 3546
- Further aseptic re-revisions n = 212
Revised for PJI
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* An index surgery is defined as a joint arthroplasty susceptible to be revised for PJI performed on patient will no previous history of revision for PJI. 
‡ This total includes the first recorded revision for PJI and any re-revision(s) for PJI. Stage one and stage two of the same two-stage revision are 
   accounted as one procedure. 
† The burden of PJI is defined as the procedures performed as a consequence of PJI: [2,926+1,113+3,546+101+39+301]+[167+73+212+1+1+4] = 8484. 
Fig. 1
description of procedures recorded in the National Joint Registry (NJR).
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primary or aseptic revision while accounting for the time 
at risk of revision for infection, the risk of death and revi-
sion for any indication other than infection. The probabil-
ity of revision for PJI at one year following a primary hip 
arthroplasty was 0.15% (95% cI 0.14 to 0.16) compared 
with 0.69% (95% cI 0.63 to 0.76) following an aseptic 
revision hip arthroplasty. At two years, the probability 
was 0.26% (95% cI 0.24 to 0.27) and 1.06% (95% cI 
0.98 to 1.14) respectively. At five years, it was 0.44% 
(95% cI 0.42 to 0.46) and 1.77% (95% cI 1.66 to 1.89), 
respectively. The probability of revision for PJI within the 
first ten years following primary hip arthroplasty was 
0.62% (95% cI 0.59 to 0.65). The ten-year probability 
following an aseptic revision was much higher, with up 
to 2.25% (95% cI 2.08 to 2.43) of those procedures sub-
sequently revised for PJI.
Healthcare service perspective. Table II shows the revi-
sion surgeries performed after primary and aseptic revi-
sion hip arthroplasty index procedures by the year the 
revision for the management of PJI was performed. All 
revision surgeries are represented, including repeated 
procedures performed to manage PJI and any subse-
quent revision procedures performed thereafter for any 
indication. To estimate the burden of infection in 2014, 
revisions performed in 2014 as a consequence of PJI, 
which either relate to index surgeries performed in 2014 
(n = 142) or cannot be linked to any index procedure 
(n = 305), were also included (fig. 1). This represents 
an estimation of the annual burden attributable to hip PJI 
at the level of england and Wales, as most of those 8484 
revisions could have been avoided if the infection had not 
occurred.
The absolute number of procedures performed as a 
consequence of infection has increased from 384 in 2005 
to 1002 in 2014, i.e. a relative increase of around 2.6. This 
is higher than the relative increase in volume of primary 
procedures observed over the same period (a two-old 
increase), but close to the increase in volume of index 
revision surgeries between 2005 and 2013 (8782 out of 
3513, a 2.5-fold increase) (Table I). While around 70% of 
those revisions are two-stage, the relative weight of 
 single-stage revisions for PJI has increased from 15.6% in 
2005 to 29.7% in 2014. dAIR with modular exchange 
procedures represents less than 4% of the total burden 
for PJI reported in the NJR between 2003 and 2014, but 
their proportion has risen from < 1% in 2005 to nearly 
4% in 2010 and 7.6% in 2014.
overall, the median interval between stages of a two-
stage revision following a primary index surgery was 105 
days (25th and 75th percentiles interquartile range (IQR) 
70 to 173). No evidence of significant temporal change 
was found, respectively 141 (IQR 111 to 203), 93 (IQR 58 
to 173), and 117 (IQR 77 to 182) in 2005, 2009 and 
2013. A median interval of 119 days (IQR 72 to 189) was 
observed for two-stage revision performed to manage PJI 
following an index aseptic revision surgery; no evidence 
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Fig. 2
Prevalence (95% confidence intervals) of revision for prosthetic joint infection within two years of the index primary surgery.
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Fig. 3
Prevalence (95% confidence intervals) of revision for prosthetic joint infection within two years of the index aseptic revision surgery.
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of a trend over time was found, 147 (IQR 63 to 280), 120 
(IQR 56 to 173), 139 (IQR 84 to 251).
Discussion
This study is the largest to date investigating the treat-
ment of hip PJI, including 686 475 index primary and 
aseptic revision hip arthroplasty procedures and 7585 
revision THAs performed due to a diagnosis of PJI. It has 
demonstrated that the probability of undergoing a revi-
sion for PJI is higher following aseptic revision hip arthro-
plasty than for primary hip arthroplasty, and that the risk 
of undergoing revision for PJI within three months of sur-
gery has risen over time for primary and revision proce-
dures. The majority of revisions performed for PJI are still 
two-stage procedures, but the use of single-stage revi-
sion is increasing. The total burden of treating PJI of the 
hip has risen substantially and this mirrors the rise in 
aseptic revision surgery recorded in the NJR rather than 
the increase in primary surgery over the period of 
observation.14
We have shown an elevated cumulative incidence rate 
of revision for PJI following aseptic revision hip arthro-
plasty (2.3% at ten years) compared with primary hip 
arthroplasty (0.6% at ten years). This is consistent with 
the findings of previous large cohort studies. In analyses 
of united states medicare data, mahomed et  al19 and 
Zhan et  al20 noted a four- to five-fold increased risk of 
wound infection within 90 days of surgery in patients 
with revision, compared with primary hip arthroplasty. 
similarly, in a united states surgical registry, both Bohl 
et al21 and Pugely et al22 observed an approximate four-
fold greater risk of deep infection in the first 30 days after 
revision, compared with primary hip arthroplasty.
Revision hip arthroplasty is performed in a population 
with increased host and procedure risk factors for infec-
tion or further revision,23 and involves prolonged opera-
tion time and also implantation of a greater volume of 
prosthetic material and adjuncts such as bone graft that 
may present a favourable environment for bacterial colo-
nisation and subsequent PJI.24
We have demonstrated a substantial time trend of an 
increased risk of revision for PJI within the first three 
months of an index procedure being performed. In their 
analysis of the Nordic Arthroplasty Register Association 
dataset, dale et al2 also noted increased revision rates due 
to hip PJI. similar to our findings, the increased risk of 
revision was mainly in the three months after the primary 
index procedure. The trend for increased risk of early revi-
sion for hip PJI is likely to be multifactorial. factors may 
include the increased accuracy of tests available to clini-
cians for the diagnosis of PJI,25 and the increased risk fac-
tors for PJI among the population undergoing hip 
arthroplasty such as elevated body mass index26 and 
increased bed occupancy.27 It may also represent a pro-
gression towards earlier recognition and/or treatment in 
specialist centres with a subsequent benefit in terms of 
reduced long-term PJI. There may be a trend towards the 
use of revision surgery to manage PJI rather than suppres-
sive treatment with antibiotics but we cannot comment 
on this as non-surgical management of PJI is not captured 
in the NJR. Risk factors recorded in the Nordic registries 
could not account for the increase in early revision rates, 
suggesting that the trend could reflect an actual increase 
in the risk of early PJI.2
The current rate of surgical revision performed as a 
consequence of hip PJI is approximately 1000 cases/year 
across the NJR. This represents a significant healthcare 
burden which has more than doubled over the last dec-
ade. The cost of revision hip arthroplasty due to PJI is 
more than three times that of primary hip arthroplasty, 
and over twice that of aseptic revision.28 In the NHs, the 
cost is in excess of £20 000 per case, not accounting for 
the litigation costs.13 single-stage revision offers an 
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Fig. 4
cumulative incidence function of revision for prosthetic joint infection fol-
lowing index primary and aseptic revision hip arthroplasty (cI, confidence 
interval).
Table ii. Number of revision procedures (n, %) performed as a consequence 
of a prosthetic joint infection (PJI) by type and year of procedure*
Year n DAiR Single-stage Two-stage Excision
2003 140 0 (0.0) 69 (49.3) 71 (50.7) 0 (0.0)
2004 270 1 (0.4) 49 (18.1) 207 (67.7) 13 (4.8)
2005 384 4 (1.0) 60 (15.6) 309 (80.5) 11 (2.9)
2006 491 5 (1.0) 69 (14.1) 399 (81.3) 18 (3.7)
2007 590 12 (2.0) 80 (13.6) 470 (79.7) 28 (4.8)
2008 748 19 (2.5) 148 (19.8) 558 (74.6) 23 (3.1)
2009 902 31 (3.4) 168 (18.6) 683 (75.7) 20 (2.2)
2010 899 35 (3.9) 209 (23.3) 629 (70.0) 26 (2.9)
2011 961 30 (3.1) 248 (25.8) 660 (68.7) 23 (2.4)
2012 1094 49 (4.5) 298 (27.2) 719 (65.7) 28 (2.6)
2013 1003 58 (5.8) 264 (26.3) 663 (66.1) 18 (1.8)
2014 1002 76 (7.6) 298 (29.7) 608 (60.7) 20 (2.0)
Total 8484 320 (3.8) 1960 (23.1) 5976 (70.4) 228 (2.7)
*this table reports the revision procedures performed after any index surgery 
revised as a consequence of PJI, including subsequent re-revision proce-
dures whether performed to manage an infection or not. It also includes the 
revision procedures performed between 2003 and 2014 on 3634 ‘infected’ 
patients with no index procedure documented in the National Joint Registry
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advantage over two-stage in both patient- and surgeon-
derived utility values in the short and long term,29 sug-
gesting that this increased burden could be mitigated by 
the increased use of single-stage revision.
We have identified an increased use of single-stage, 
as compared with two-stage, revision for hip PJI. 
currently in the NJR, the only option to record dAIR 
with modular exchange procedures is to record them as 
single-stage revisions.30 This complicates their differen-
tiation from single-stage surgeries where implants fixed 
to bone such as a acetabular component and stem (dis-
tal or non- modular) are revised. This represents a poten-
tial weakness of the data collection form as this may be 
subject to different interpretation by surgeons, despite 
the fact that recording of procedures in which any com-
ponent is removed or inserted is mandatory. We have 
used component-level data for individual cases to iden-
tify dAIR procedures with modular exchange. A few 
single-stage revisions for PJI unlinked to an index proce-
dure were considered as dAIRs in view of the compo-
nents implanted (n = 43).
The importance of arthroplasty registries in identifying 
best clinical practice and improving health outcomes is 
recognised.31 The NJR is one of the largest joint arthro-
plasty registers, with comprehensive coverage of proce-
dures undertaken, which is reassuring in terms of the 
generalisability of the data generated by the study. Issues 
relating to under-reporting, and thus potentially lower 
incidence estimates, are acknowledged.32 The data are 
prospectively entered into the registry and are observa-
tional which implies certain limitations. The recording of 
PJI as an indication for surgery is at the discretion of the 
treating surgeon at the time of surgery. As such, the diag-
nosis has not necessarily been referenced against a 
benchmark set of criteria and hence may be subject to 
misdiagnosis. linkage to multiple other datasets, includ-
ing those containing microbiology data and results, may 
improve the sensitivity and specificity of the diagnosis of 
PJI in these cases.33 While the NJR now represents a 
mature dataset with long-term follow-up, there is still a 
substantial number of patients undergoing revision hip 
arthroplasty with no record of a linked primary hip arthro-
plasty. As anonymised data were provided to us, it is dif-
ficult to determine to what extent this might be due to 
issues related to the patient identification and linkage to 
their related index procedures in the original dataset. This 
is reflective of the fact that some PJI revisions were per-
formed in the early days of the registry and relate to index 
procedures performed prior to the start of the registry or 
at a time data capture was still improving but incom-
plete. The proportion of patients with a revision for PJI 
reported in the NJR but unlinked to an index surgery has 
indeed reduced over time: from 79% in 2005 compared 
with 46% in 2009 and 36% in 2014. survivorship of hip 
arthroplasty is high14 and it is also likely that some 
PJI revision procedures occur a long time after the index 
procedure due to PJI secondary to haematogenous 
spread: around 21% (280/1345) of revision procedures 
for PJI have been reported at greater than two years after 
the index surgery,34 with 10% performed at five years or 
beyond. The sample we present is six times larger than 
previous reports and therefore it is likely that a certain 
volume of our unlinked procedures are late revisions of 
index procedures performed before 2003 or in the first 
years of the registry.
The number of revisions performed annually in 
england and Wales for infected hip arthroplasties is ris-
ing, as is the risk of revision for infection in the first three 
months following surgery. This has substantial implica-
tions for service delivery given the surgical burden and 
costs associated with performing revision hip arthroplas-
ties for prosthetic joint infection. single-stage revisions 
are still performed less frequently than two-stage revi-
sions but are becoming more popular.
Supplementary material
figures showing prevalence (95% cI) of revision for 
prosthetic joint infection are available alongside this 
article at www.bjr.boneandjoint.org.uk
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